Twinrix: Difference between revisions
No edit summary |
|||
| Line 9: | Line 9: | ||
The [[Centers_for_Disease_Control_and_Prevention|CDC]] reports that clinical trials found the following levels of protection against Hep A and Hep B one month after each dose<ref>http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5037a4.htm</ref>:<br> | The [[Centers_for_Disease_Control_and_Prevention|CDC]] reports that clinical trials found the following levels of protection against Hep A and Hep B one month after each dose<ref>http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5037a4.htm</ref>:<br> | ||
A: 93.8% 98.8% 99.9%<br> | A: 93.8% 98.8% 99.9%<br> | ||
B: 30.8% 78.2% 98.5% | B: 30.8% 78.2% 98.5%<br> | ||
GlaxoSmithKline claims that its studies found 70% of subjects had antibodies against hepatitis B a month after just the first dose, however.<ref>http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=2061#PHARMACOLOGICAL_PROPS</ref> | GlaxoSmithKline claims that its studies found 70% of subjects had antibodies against hepatitis B a month after just the first dose, however.<ref>http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=2061#PHARMACOLOGICAL_PROPS</ref> | ||
Latest revision as of 15:51, 2 January 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Twinrix is a vaccine against hepatitis A and hepatitis B. Twinrix is administered over three doses.
The name was created because it is a mixture of two earlier vaccines - Havrix, an inactivated-virus Hepatitis A vaccine, and ENGERIX-B, a recombinant Hepatitis B vaccine.
The CDC reports that clinical trials found the following levels of protection against Hep A and Hep B one month after each dose[1]:
A: 93.8% 98.8% 99.9%
B: 30.8% 78.2% 98.5%
GlaxoSmithKline claims that its studies found 70% of subjects had antibodies against hepatitis B a month after just the first dose, however.[2]
TWINRIX, HAVRIX and ENGERIX-B are registered trademarks of GlaxoSmithKline; if the same vaccine is available from others, it will have another name.